Navigation Links
Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors

Peake to provide guidance and direction regarding military needs, clinical uses and funding sources

ROCKVILLE, Md., June 30 /PRNewswire/ -- Cellphire, Inc., a biotechnology company located in Rockville, Md., announced today that former Secretary of the Department of Veterans Affairs, James Peake, MD, has joined its board of directors.

"I am excited about the potential of Thrombosomes(R) to save lives on the battlefield and in emergency rooms throughout the US. I am eager to contribute to the effort to conduct appropriate clinical trials to evaluate and ultimately field this product," said Dr. Peake.

Cellphire is committed to developing a freeze-dried platelet product, Thrombosomes(R), which could potentially be effective in stopping uncontrollable bleeding on the battlefield or in trauma. Platelets can only be stored for 5 days and cannot be provided to combat zones, although in-the-field harvesting is being performed. Cellphire's product is expected to have a 12 month shelf life and be immediately available for infusion after adding sterile water.

"We are excited about the addition of Dr. Peake to the Cellphire Board," said Cellphire President Mike Fitzpatrick. "With his incomparable experience and tireless commitment to providing the best possible care for the active duty uniformed services and veterans, we feel sure his contributions will help us achieve our goal."

Dr. Peake is a retired U.S. Army Lieutenant General; he was selected as the U.S. Army Surgeon General. After retirement from the Army he served as the Executive Vice President and Chief Operating Officer of Project Hope and most recently as the Secretary of the U.S. Department of Veterans Affairs. A native of St. Louis and graduate of the U.S. Military Academy at West Point, Peake attended medical school after serving in Vietnam with the 101st Airborne Division, where he was awarded the Silver Star and Purple Heart.

About Cellphire

Cellphire, Inc., a biotechnology company, is focused on developing stabilized cellular materials for advanced technologies in the therapeutic and diagnostic markets. Current efforts and product development are aimed toward stabilized platelets for advanced wound care, transfusion, and reagent products for clinical and research diagnostics.

For more information please visit:

SOURCE Cellphire, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus
2. Former EPA official calls for new environmental and consumer protection agency
3. Cliff Consulting, Inc. Adds Former Banking IT Executive Ashok Moorthy to Its Team
4. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
5. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
6. Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
7. Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise
8. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
9. Former SADMERC Medical Directors Join OrthoCare Innovations as Medical and Scientific Advisory Board Members and Strategic Advisors
10. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
11. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
Post Your Comments:
(Date:11/30/2015)... Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that ... its Board of Directors to replace Dr. Peter Johann ... experience as co-founder of Resverlogix, with expertise in the fields ... --> Dr. Wong remarked, "I am very excited ... standing expertise in epigenetics and the advanced stage of the ...
(Date:11/30/2015)... , November 30, 2015 TapImmune, ... the development of innovative peptide and gene-based immunotherapeutics and ... today announced it will be presenting at the 8 ... 1, 2015 at 2.30 PM PT. Dr. John ... Advisor will be giving the presentation and will join ...
(Date:11/30/2015)... BETHESDA, Md. , Nov. 30, 2015  Northwest ... biotechnology company developing DCVax® personalized immune therapies for solid ... to adding an additional independent director, and the Company ... investigation of allegations in a recent anonymous internet report ... on both initiatives. Linda Powers stated, ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, and ... covers a wide range of applications such as, but not limited to, biotechnology, ...
Breaking Biology Technology:
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
(Date:10/27/2015)... NEW YORK , Oct. 27, 2015 ... the major issues of concern for various industry verticals ... This is due to the growing demand for secure ... practices in various ,sectors, such as hacking of bank ... concerns for electronic equipment such as PC,s, laptops, and ...
Breaking Biology News(10 mins):